Response rates after transplantation in the matched control study
| Response, n (%) . | All patients . | VAD induction . | Bor/Dex induction . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IFM 2005-01 (n = 115) . | Bor-HDM (n = 46) . | P . | IFM 2005-01 (n = 70) . | Bor-HDM (n = 28) . | P . | IFM 2005-01 (n = 45) . | Bor-HDM (n = 18) . | P . | |
| CR | 13 (11) | 16 (35) | .001 | 7 (10) | 9 (32) | .013 | 6 (13) | 7 (39) | .038 |
| VGPR* | 49 (43) | 16 (35) | 23 (33) | 10 (36) | 26 (58) | 6 (33) | |||
| PR | 50 (43) | 12 (26) | 38 (54) | 7 (25) | 12 (27) | 5 (28) | |||
| SD | 3 (3) | 2 (4) | 2 (3) | 2 (7) | 1 (2) | 0 | |||
| CR + VGPR | 62 (54) | 32 (70) | .078 | 30 (43) | 19 (68) | .043 | 32 (71) | 13 (72) | |
| Response, n (%) . | All patients . | VAD induction . | Bor/Dex induction . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IFM 2005-01 (n = 115) . | Bor-HDM (n = 46) . | P . | IFM 2005-01 (n = 70) . | Bor-HDM (n = 28) . | P . | IFM 2005-01 (n = 45) . | Bor-HDM (n = 18) . | P . | |
| CR | 13 (11) | 16 (35) | .001 | 7 (10) | 9 (32) | .013 | 6 (13) | 7 (39) | .038 |
| VGPR* | 49 (43) | 16 (35) | 23 (33) | 10 (36) | 26 (58) | 6 (33) | |||
| PR | 50 (43) | 12 (26) | 38 (54) | 7 (25) | 12 (27) | 5 (28) | |||
| SD | 3 (3) | 2 (4) | 2 (3) | 2 (7) | 1 (2) | 0 | |||
| CR + VGPR | 62 (54) | 32 (70) | .078 | 30 (43) | 19 (68) | .043 | 32 (71) | 13 (72) | |
VAD indicates vincristine, Adriamycin, and dexamethasone; Bor/Dex, bortezomib and dexamethasone; IFM, Intergroupe Francophone du Myélome; Bor-HDM, bortezomib and high-dose melphalan; CR, complete response; VGPR, very good partial response; PR, partial response; and SD, stable disease.
Ten patients with negative immunofixation but without bone marrow evaluation were assessed as VGPR, including 3 patients (6.5%) in the Bor-HDM study and 7 patients (6%) in the IFM 2005-01 trial.